Novo invested in liver disease drug developer Mirum Pharmaceuticals as part of the round while Shire acquired an equity stake in the startup through a licensing deal.
US-based liver disease treatment developer Mirum Pharmaceuticals raised $120m yesterday in a series A round led by venture capital firm New Enterprise Associates (NEA) that included pharmaceutical firm Novo.
Hedge fund sponsor Deerfield Management, growth equity firm Frazier Healthcare Partners, investment firm Rock Springs Capital and life sciences venture capital firms Pappas Capital and RiverVest Venture Partners also took part in the round.
Mirum is working on Maralixibat, an oral inhibitor that could help prevent the build-up of bile acids…
